RADNOR, Pa., Oct. 24, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a clinical stage biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, presented clinical and pre-clinical data related to the spectrum of activity and safety of its novel defensin-mimetic antibiotic, PMX-30063. The data was presented in poster format at the 49th annual meeting of the Infectious Disease Society of America (IDSA) and the HIV Medicine Association in Boston on October 21, 2011. PMX-30063 is currently in a multi-national Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections caused by Staph aureus bacteria.
